Canada In Vitro Diagnostics Market Outlook to 2018- Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry and Microbiology Culture

Date: November 30, 2012
Pages: 279
Price:
US$ 2,500.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: C2EDFCDA0E3EN
Leaflet:

Download PDF Leaflet

Canada In Vitro Diagnostics Market Outlook to 2018- Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry and Microbiology Culture
Canada In Vitro Diagnostics Market Outlook to 2018- Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture

Summary

GlobalData’s new report, “Canada In Vitro Diagnostics Market Outlook to 2018- Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture” provides key market data on the Canada In Vitro Diagnostics market. The report provides value (USD million) data for each segment and sub-segment within seven market categories – Clinical Chemistry, Genetic Testing, Haematology, Histology And Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture. The report also provides company shares and distribution shares data for each of the aforementioned market categories. The report is supplemented with global corporate-level profiles of the key market participants with information on company financials and pipeline products, wherever available.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope
  • Market size and company share data for In Vitro Diagnostics market categories – Clinical Chemistry, Genetic Testing, Haematology, Histology And Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture.
  • Annualized market revenues (USD million) data for each of the segments and sub-segments within seven market categories. Data from 2004 to 2011, forecast forward for 7 years to 2018.
  • 2011 company shares and distribution shares data for each of the seven market categories.
  • Global corporate-level profiles of key companies operating within the Canada In Vitro Diagnosticsmarket.
  • Key players covered include Siemens Healthcare, Abbott Laboratories, F. Hoffmann-La Roche Ltd., Beckman Coulter, Inc., Ortho-Clinical Diagnostics Inc., Alere Inc. and others.
Reasons to buy
  • Develop business strategies by identifying the key market categories and segments poised for strong growth.
  • Develop market-entry and market expansion strategies.
  • Design competition strategies by identifying who-stands-where in the Canada In Vitro Diagnostics competitive landscape.
  • Develop capital investment strategies by identifying the key market segments expected to register strong growth in the near future.
  • What are the key distribution channels and what’s the most preferred mode of product distribution – Identify, understand and capitalize.
1 TABLE OF CONTENTS

1.1 List of Tables
1.2 List of Figures

2 INTRODUCTION

2.1 What is This Report About?

3 IN VITRO DIAGNOSTICS IN CANADA

3.1 In Vitro Diagnostics, Market Segmentation
3.2 In Vitro Diagnostics, Canada, Overall Revenue ($m) , USD Constant, 2004-2018
3.3 In Vitro Diagnostics Market, Canada, Revenue Mix ($m), 2011
3.4 In Vitro Diagnostics Market, Canada, Category Contribution (%), 2011
3.5 In Vitro Diagnostics, Canada, Company Share (2010-2011)

4 CLINICAL CHEMISTRY IN CANADA

4.1 Clinical Chemistry, Market Segmentation
4.2 Clinical Chemistry Market, Canada, Revenue Mix ($m), 2011
4.3 Clinical Chemistry Market, Canada, Segment Contribution (%), 2011
4.4 Clinical Chemistry Overall Revenue, (2004-2018)
  4.4.1 Clinical Chemisty Analyzers, Revenue (2004-2018)
  4.4.2 Urine Analysis, Revenue (2004-2018)
4.5 Clinical Chemistry Distribution Share (2010-2011)
4.6 Clinical Chemistry, Canada, Company Share (2010-2011)

5 GENETIC TESTING IN CANADA

5.1 Genetic Testing, Market Segmentation
5.2 Genetic Testing Market, Canada, Revenue Mix ($m), 2011
5.3 Genetic Testing Market, Canada, Segment Contribution (%), 2011
5.4 Genetic Testing Overall Revenue, (2004-2018)
5.5 Genetic Testing Distribution Share (2010-2011)
5.6 Genetic Testing, Canada, Company Share (2010-2011)

6 HAEMATOLOGY IN CANADA

6.1 Haematology Market, Market Segmentation
6.2 Haematology Market, Canada, Revenue Mix ($m), 2011
6.3 Haematology Market, Canada, Segment Contribution (%), 2011
6.4 Haematology Overall Revenue, (2004-2018)
  6.4.1 Haematology Reagents, Revenue (2004-2018)
  6.4.2 Immunohaematology, Revenue (2004-2018)
  6.4.3 Haemostasis, Revenue (2004-2018)
  6.4.4 Haematology Rapid Tests, Revenue (2004-2018)
  6.4.5 Haematology Cell Counters, Revenue (2004-2018)
6.5 Haematology Distribution Share (2010-2011)
6.6 Haematology, Canada, Company Share (2010-2011)

7 HISTOLOGY AND CYTOLOGY IN CANADA

7.1 Histology and Cytology Market, Market Segmentation
7.2 Histology And Cytology Market, Canada, Revenue Mix ($m), 2011
7.3 Histology And Cytology Market, Canada, Segment Contribution (%), 2011
7.4 Histology And Cytology Overall Revenue, (2004-2018)
7.5 Histology And Cytology Distribution Share (2010-2011)
7.6 Histology And Cytology, Canada, Company Share (2010-2011)

8 IMMUNO CHEMISTRY IN CANADA

8.1 Immuno Chemistry Market, Canada, Revenue Mix ($m), 2011
8.2 Immuno Chemistry Market, Canada, Segment Contribution (%), 2011
8.3 Immuno Chemistry Overall Revenue, (2004-2018)
  8.3.1 Disease Specific Immunochemistry, Revenue (2004-2018)
  8.3.2 Drugs of Abuse / Toxicology, Revenue (2004-2018)
  8.3.3 Endocrinology Tests, Revenue (2004-2018)
  8.3.4 Immunochemistry Rapid Tests, Revenue (2004-2018)
  8.3.5 Therapeutic Drug Monitoring, Revenue (2004-2018)
  8.3.6 Immunochemistry Analyzers, Revenue (2004-2018)
8.4 Immuno Chemistry Distribution Share (2010-2011)
8.5 Immuno Chemistry, Canada, Company Share (2010-2011)

9 INFECTIOUS IMMUNOLOGY IN CANADA

9.1 Infectious Immunology, Market Segmentation
9.2 Infectious Immunology Market, Canada, Revenue Mix ($m), 2011
9.3 Infectious Immunology Market, Canada, Segment Contribution (%), 2011
9.4 Infectious Immunology Overall Revenue, (2004-2018)
  9.4.1 Infectious Immunology Rapid Tests, Revenue (2004-2018)
9.5 Infectious Immunology Distribution Share (2010-2011)
9.6 Infectious Immunology, Canada, Company Share (2010-2011)

10 MICROBIOLOGY CULTURE IN CANADA

10.1 Microbiology Culture, Market Segmentation
10.2 Microbiology Culture Market, Canada, Revenue Mix ($m), 2011
10.3 Microbiology Culture Market, Canada, Segment Contribution (%), 2011
10.4 Microbiology Culture Overall Revenue, (2004-2018)
  10.4.1 Microbiology Analyzers, Revenue (2004-2018)
10.5 Microbiology Culture Distribution Share (2010-2011)
10.6 Microbiology Culture, Canada, Company Share (2010-2011)

11 OVERVIEW OF KEY COMPANIES IN CANADA IN VITRO DIAGNOSTICS MARKET

11.1 Siemens Healthcare
  11.1.1 Company Overview
  11.1.2 Share in the Canada In Vitro Diagnostics Market
11.2 Abbott Laboratories
  11.2.1 Company Overview
  11.2.2 Share in the Canada In Vitro Diagnostics Market
11.3 F. Hoffmann-La Roche Ltd.
  11.3.1 Company Overview
  11.3.2 Share in the Canada In Vitro Diagnostics Market
11.4 Beckman Coulter, Inc.
  11.4.1 Company Overview
  11.4.2 Share in the Canada In Vitro Diagnostics Market
11.5 Ortho-Clinical Diagnostics Inc.
  11.5.1 Company Overview
  11.5.2 Share in the Canada In Vitro Diagnostics Market
11.6 Alere Inc.
  11.6.1 Company Overview
  11.6.2 Share in the Canada In Vitro Diagnostics Market
11.7 Danaher Corporation.
  11.7.1 Company Overview
11.8 bioMerieux S.A.
  11.8.1 Company Overview
11.9 Becton, Dickinson and Company
  11.9.1 Company Overview
11.10 Bio-Rad Laboratories, Inc.
  11.10.1 Company Overview
11.11 Biomedica Diagnostics Inc.
  11.11.1 Company Overview
11.12 Sysmex Corporation
  11.12.1 Company Overview
11.13 Gen-Probe Incorporated
  11.13.1 Company Overview
11.14 Qiagen N.V.
  11.14.1 Company Overview
11.15 DiaSorin S.p.A
  11.15.1 Company Overview
11.16 Thermo Fisher Scientific Inc.
  11.16.1 Company Overview
11.17 Immucor, Inc.
  11.17.1 Company Overview
11.18 Hologic, Inc.
  11.18.1 Company Overview
11.19 Olympus Corporation
  11.19.1 Company Overview
11.20 PerkinElmer, Inc.
  11.20.1 Company Overview
11.21 Grifols, S.A.
  11.21.1 Company Overview
11.22 Life Technologies Corporation
  11.22.1 Company Overview
11.23 ELITech Group
  11.23.1 Company Overview
11.24 Horiba, Ltd.
  11.24.1 Company Overview
11.25 Diagnostica Stago, Inc.
  11.25.1 Company Overview

12 IN VITRO DIAGNOSTICS MARKET PIPELINE PRODUCTS

12.1 Clinical Chemisty Market Pipeline Products
12.2 Immuno Chemistry Market Pipeline Products
12.3 Haematology Market Pipeline Products
12.4 Infectious Immunology Market Pipeline Products
12.5 Microbiology Culture Market Pipeline Products
12.6 Histology And Cytology Market Pipeline Products
12.7 Genetic Testing Market Pipeline Products

13 FINANCIAL DEALS LANDSCAPE

13.1 Acquisition
  13.1.1 Maxxam Analytics Acquires Becquerel Labs, Provider Of Testing Services
  13.1.2 Ontario Genomics Institute Acquires Minority Stake In RNA Diagnostics For $0.1 Million
13.2 Partnerships
  13.2.1 Malvern Instruments Enters Into Co-Marketing Agreement With Affinity Biosensors For Archimedes Particle Metrology System
  13.2.2 Agenix Enters Into Licensing Agreement With Tyrian Diagnostics For DiagnostIQ
  13.2.3 BioDot Enters Into Co-Marketing Agreement With JOT Automation
  13.2.4 BD Diagnostic Systems Enters Into Agreement With Lab21 To Develop New Oncology Assays
  13.2.5 Med BioGene Amends Licensing Agreement With Precision Therapeutics For LungExpress Dx Test
  13.2.6 Proof Centre Enters Into Co-Development Agreement With AllerGen For Allergy Biomarkers
  13.2.7 Ovizio Imaging Systems Enters Into Distribution Agreement With Applikon Biotechnology
  13.2.8 Atossa Enters Into Co-Marketing Agreement With Diagnostics Test Group For MASCT System
  13.2.9 CML HealthCare Enters Into Agreement With MaRS Innovation
  13.2.10 Agilent Technologies Enters Into Co-Marketing Agreement With MRM Proteomics
  13.2.11 Castle Biosciences Enters Into Licensing Agreement With Brigham and Women's Hospital For Mesothelioma Test
  13.2.12 Scienion Enters Into Co-Marketing Agreement With Maine Manufacturing For Protein Array Products
  13.2.13 GeneCentric Diagnostics Enters Into Licensing Agreement With University of North Carolina
  13.2.14 Axela Enters Into Co-Marketing Agreement With OvaGene Oncology
  13.2.15 Epistem Enters Into Distribution Agreement With Becton Dickinson For Mycobacterium TB Test
  13.2.16 OriGene Technologies Enters Into Co-Development Agreement With Centre of Excellence for Prevention of Organ Failure
  13.2.17 SciFluor Life Sciences Enters Into Distribution Agreement With Sigma-Aldrich For PhenoFluor
  13.2.18 Immuno-Biological Labs Enters Into Licensing Agreement With IBL International
  13.2.19 MDxHealth Enters Into Licensing Agreement With Merck For MGMT Diagnostic Test
  13.2.20 CogState Enters Into Licensing Agreement With Merck Canada For Cognition Test
  13.2.21 NicOx Enters Into Licensing Agreement With Rapid Pathogen Screening For AdenoPlus
  13.2.22 Immunexpress Enters Into Licensing Agreement With Debiopharm And Biocartis
  13.2.23 Omega Diagnostics Enters Into Licensing Agreement With Burnet Institute For CD4 POC Test
  13.2.24 One Lambda Enters Into Co-Marketing Agreement With CellTrend
  13.2.25 Clarient Diagnostic Services Enters Into Licensing Agreement With Insight Genetics For ALK Cancer Biomarker
  13.2.26 Affymetrix Enters Into Technology Integration Agreement With Leica Microsystems
  13.2.27 Ventana Medical Enters Into Licensing Agreement With Gen-Probe For IP Of ERG Marker
  13.2.28 Affymetrix Enters Into Distribution Agreement With ScreenCell For Circulating Tumor Cell Technology
  13.2.29 Hycor Biomedical Enters Into Distribution Agreement With Roche For KOVA
  13.2.30 Genome Diagnostics Enters Into Co-Marketing Agreement With Qiagen For LongRange PCR Kit
  13.2.31 Biofortuna Extends Co-Marketing Agreement With Abbott Labs For SSPGo
  13.2.32 Pressure BioSciences Enters Into Licensing Agreement With Target Discovery For Pressure Cycling Technology
  13.2.33 LipoScience Enters Into Licensing Agreement With Cleveland Clinic
  13.2.34 GE Healthcare Enters Into Co-Development Agreement With NXT2B For Compact Cyclotron And PET Tracer System
  13.2.35 Miraculins Enters Into Co-Marketing Agreement With Pear Healthcare Solutions For PreVu
  13.2.36 NexDx Enters Into Licensing Agreement With University of California For Epigenetic Biomarkers
  13.2.37 Stellar Biotechnologies Enters Into Option Licensing Agreement With University of Guelph For Clostridium Difficile Technology
  13.2.38 Centre of Excellence for Prevention of Organ Failure Enters Into Co-Development Agreement With Adiga Life Sciences For Proteomic And Genomic Biomarkers
  13.2.39 Bio-Rad Labs Extends Distribution Agreement With Luminex For MAGPIX
  13.2.40 LabCorp Enters Into Licensing Agreement With OPKO Health For Alzheimer's Diagnostic Technology
  13.2.41 AEterna Zentaris Enters Into Co-Development Agreement With Ventana Medical Systems
  13.2.42 Sony DADC Enters Into Co-Development Agreement With Axela
  13.2.43 Genome British Columbia Enters Into Co-Development Agreement With Genome Canada

14 RECENT DEVELOPMENTS

14.1 Strategy And Business Planning
  14.1.1 Sep 18, 2012: CML HealthCare Announces Strategic Plan And Senior Management Enhancements
  14.1.2 Sep 12, 2012: Nordion Announces Strategic Realignment Of Business
  14.1.3 Dec 20, 2011: Warnex To Sell Analytical Services Division
  14.1.4 Nov 30, 2011: SQI Diagnostics Announces Realignment Of Business And Reductions In Operating Expenses To Better Serve Its IVD And CustomPlex Businesses
14.2 Government and Public Interest
  14.2.1 Jun 21, 2012: Blood Test For Pregnant Women Could Predict Risk Of Having Dangerously Small Babies
  14.2.2 Jun 05, 2012: Blood Test Identifies Increased Risk Of Death Following Surgery: McMaster Researchers
  14.2.3 May 07, 2012: PSA Screening To Detect Prostate Cancer Can Be Beneficial To Younger And At-Risk Men: New Study
  14.2.4 Mar 29, 2012: Complete Genomics Accepts DNA Obtained From Saliva For Whole Human Genome Sequencing
  14.2.5 Jan 27, 2012: Bruker And SAT Announce Joint Publication On SISCAPA-MALDI-TOF Mass Spectrometry For Biomarker Validation And Clinical Research
  14.2.6 Jan 24, 2012: RI-MUHC-Led Study Compares Saliva Self-Test To Blood Test
  14.2.7 Dec 21, 2011: Miraculins Successfully Passes Critical ISO 13485 Certification Audit
14.3 Product News
  14.3.1 Nov 08, 2012: Roche Receives Health Canada Approval For Cobas AmpliPrep/Cobas TaqMan CMV Test
  14.3.2 Oct 29, 2012: Epocal Receives FDA Clearance For Creatinine Test
  14.3.3 Oct 29, 2012: Epocal Receives FDA Clearance For Chloride Test
  14.3.4 Sep 26, 2012: Aeterna Zentaris Provides Update On NDA Filing For AEZS-130 As Diagnostic Test For Adult Growth Hormone Deficiency
  14.3.5 Aug 13, 2012: Miraculins To Launch PreVu Skin Cholesterol Test In Canada Through London Drugs
  14.3.6 Jul 24, 2012: Aeterna Zentaris Requests Fast Track Designation From FDA For AEZS-130 As Diagnostic Test For AGHD
  14.3.7 Jul 23, 2012: FDA Grants CLIA Waiver To bioLytical INSTI Rapid HIV Test
  14.3.8 May 03, 2012: DNA Genotek Announces Recipients Of DNA Genotek Grant Program
  14.3.9 Mar 21, 2012: New Studies Demonstrate Clinical Utility And Validity Of CancerType ID Molecular Classifier
  14.3.10 Feb 01, 2012: Miraculins Receives Health Canada Approval To Market For PreVu POC Test
  14.3.11 Dec 19, 2011: British Columbia Cancer Agency Joins Illumina Genome Network

15 APPENDIX

15.1 Definitions of Markets Covered in the Report
  15.1.1 In Vitro Diagnostics
15.2 Research Methodology
15.3 Secondary Research
15.4 Primary Research
15.5 Models
15.6 Forecasts
15.7 Expert Panels
15.8 GlobalData Consulting
15.9 Currency Conversion
15.10 Contact Us
15.11 Disclaimer

LIST OF TABLES

Table 1: In Vitro Diagnostics, Canada, Overall Revenue ($m) , USD Constant, 2004-2018
Table 2: In Vitro Diagnostics Market, Canada, Category Contribution (%), 2011
Table 3: In Vitro Diagnostics Market, Canada, Cross-Category Analysis, 2004-2018
Table 4: In Vitro Diagnostics, Canada, Overall Revenue ($m), USD Constant, Historic, 2004-2011
Table 5: In Vitro Diagnostics, Canada, Overall Revenue ($m), USD Constant, Forecast, 2011-2018
Table 6: In Vitro Diagnostics, Canada, Company Share by Revenue ($m), USD Constant, 2010-2011
Table 7: Clinical Chemistry Market, Canada, Segment Contribution (%), 2011
Table 8: Clinical Chemistry, Canada, Revenue ($m) USD Constant, by Segment , Historic, 2004-2011
Table 9: Clinical Chemistry, Canada, Revenue ($m) USD Constant, by Segment , Forecast, 2011-2018
Table 10: Clinical Chemisty Analyzers, Canada, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Table 11: Clinical Chemisty Analyzers, Canada, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Table 12: Urine Analysis, Canada, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Table 13: Urine Analysis, Canada, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Table 14: Clinical Chemistry, Canada, Distribution Share by Revenue ($m), USD Constant, 2010-2011
Table 15: Clinical Chemistry, Canada, Company Share by Revenue ($m), USD Constant, 2010-2011
Table 16: Genetic Testing Market, Canada, Segment Contribution (%), 2011
Table 17: Genetic Testing, Canada, Revenue ($m) USD Constant, by Segment , Historic, 2004-2011
Table 18: Genetic Testing, Canada, Revenue ($m) USD Constant, by Segment , Forecast, 2011-2018
Table 19: Genetic Testing, Canada, Distribution Share by Revenue ($m), USD Constant, 2010-2011
Table 20: Genetic Testing, Canada, Company Share by Revenue ($m), USD Constant, 2010-2011
Table 21: Haematology Market, Canada, Segment Contribution (%), 2011
Table 22: Haematology, Canada, Revenue ($m) USD Constant, by Segment , Historic, 2004-2011
Table 23: Haematology, Canada, Revenue ($m) USD Constant, by Segment , Forecast, 2011-2018
Table 24: Haematology Reagents, Canada, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Table 25: Haematology Reagents, Canada, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Table 26: Immunohaematology, Canada, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Table 27: Immunohaematology, Canada, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Table 28: Haemostasis, Canada, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Table 29: Haemostasis, Canada, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Table 30: Haematology Rapid Tests, Canada, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Table 31: Haematology Rapid Tests, Canada, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Table 32: Haematology Cell Counters, Canada, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Table 33: Haematology Cell Counters, Canada, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Table 34: Haematology, Canada, Distribution Share by Revenue ($m), USD Constant, 2010-2011
Table 35: Haematology, Canada, Company Share by Revenue ($m), USD Constant, 2010-2011
Table 36: Histology And Cytology Market, Canada, Segment Contribution (%), 2011
Table 37: Histology And Cytology, Canada, Revenue ($m) USD Constant, by Segment , Historic, 2004-2011
Table 38: Histology And Cytology, Canada, Revenue ($m) USD Constant, by Segment , Forecast, 2011-2018
Table 39: Histology And Cytology, Canada, Distribution Share by Revenue ($m), USD Constant, 2010-2011
Table 40: Histology And Cytology, Canada, Company Share by Revenue ($m), USD Constant, 2010-2011
Table 41: Immuno Chemistry Market, Canada, Segment Contribution (%), 2011
Table 42: Immuno Chemistry, Canada, Revenue ($m) USD Constant, by Segment , Historic, 2004-2011
Table 43: Immuno Chemistry, Canada, Revenue ($m) USD Constant, by Segment , Forecast, 2011-2018
Table 44: Disease Specific Immunochemistry, Canada, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Table 45: Disease Specific Immunochemistry, Canada, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Table 46: Drugs of Abuse / Toxicology, Canada, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Table 47: Drugs of Abuse / Toxicology, Canada, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Table 48: Endocrinology Tests, Canada, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Table 49: Endocrinology Tests, Canada, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Table 50: Immunochemistry Rapid Tests, Canada, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Table 51: Immunochemistry Rapid Tests, Canada, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Table 52: Therapeutic Drug Monitoring, Canada, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Table 53: Therapeutic Drug Monitoring, Canada, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Table 54: Immunochemistry Analyzers, Canada, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Table 55: Immunochemistry Analyzers, Canada, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Table 56: Immuno Chemistry, Canada, Distribution Share by Revenue ($m), USD Constant, 2010-2011
Table 57: Immuno Chemistry, Canada, Company Share by Revenue ($m), USD Constant, 2010-2011
Table 58: Infectious Immunology Market, Canada, Segment Contribution (%), 2011
Table 59: Infectious Immunology, Canada, Revenue ($m) USD Constant, by Segment , Historic, 2004-2011
Table 60: Infectious Immunology, Canada, Revenue ($m) USD Constant, by Segment , Forecast, 2011-2018
Table 61: Infectious Immunology Rapid Tests, Canada, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Table 62: Infectious Immunology Rapid Tests, Canada, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Table 63: Infectious Immunology, Canada, Distribution Share by Revenue ($m), USD Constant, 2010-2011
Table 64: Infectious Immunology, Canada, Company Share by Revenue ($m), USD Constant, 2010-2011
Table 65: Microbiology Culture Market, Canada, Segment Contribution (%), 2011
Table 66: Microbiology Culture, Canada, Revenue ($m) USD Constant, by Segment , Historic, 2004-2011
Table 67: Microbiology Culture, Canada, Revenue ($m) USD Constant, by Segment , Forecast, 2011-2018
Table 68: Microbiology Analyzers, Canada, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Table 69: Microbiology Analyzers, Canada, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Table 70: Microbiology Culture, Canada, Distribution Share by Revenue ($m), USD Constant, 2010-2011
Table 71: Microbiology Culture, Canada, Company Share by Revenue ($m), USD Constant, 2010-2011
Table 72: Clinical Chemisty Market Pipeline Products
Table 73: Immuno Chemistry Market Pipeline Products
Table 74: Haematology Market Pipeline Products
Table 75: Infectious Immunology Market Pipeline Products
Table 76: Microbiology Culture Market Pipeline Products
Table 77: Histology And Cytology Market Pipeline Products
Table 78: Genetic Testing Market Pipeline Products
Table 79: Maxxam Analytics Acquires Becquerel Labs, Provider Of Testing Services
Table 80: Ontario Genomics Institute Acquires Minority Stake In RNA Diagnostics For $0.1 Million
Table 81: Malvern Instruments Enters Into Co-Marketing Agreement With Affinity Biosensors For Archimedes Particle Metrology System
Table 82: Agenix Enters Into Licensing Agreement With Tyrian Diagnostics For DiagnostIQ
Table 83: BioDot Enters Into Co-Marketing Agreement With JOT Automation
Table 84: BD Diagnostic Systems Enters Into Agreement With Lab21 To Develop New Oncology Assays
Table 85: Med BioGene Amends Licensing Agreement With Precision Therapeutics For LungExpress Dx Test
Table 86: Proof Centre Enters Into Co-Development Agreement With AllerGen For Allergy Biomarkers
Table 87: Ovizio Imaging Systems Enters Into Distribution Agreement With Applikon Biotechnology
Table 88: Atossa Enters Into Co-Marketing Agreement With Diagnostics Test Group For MASCT System
Table 89: CML HealthCare Enters Into Agreement With MaRS Innovation
Table 90: Agilent Technologies Enters Into Co-Marketing Agreement With MRM Proteomics
Table 91: Castle Biosciences Enters Into Licensing Agreement With Brigham and Women's Hospital For Mesothelioma Test
Table 92: Scienion Enters Into Co-Marketing Agreement With Maine Manufacturing For Protein Array Products
Table 93: GeneCentric Diagnostics Enters Into Licensing Agreement With University of North Carolina
Table 94: Axela Enters Into Co-Marketing Agreement With OvaGene Oncology
Table 95: Epistem Enters Into Distribution Agreement With Becton Dickinson For Mycobacterium TB Test
Table 96: OriGene Technologies Enters Into Co-Development Agreement With Centre of Excellence for Prevention of Organ Failure
Table 97: SciFluor Life Sciences Enters Into Distribution Agreement With Sigma-Aldrich For PhenoFluor
Table 98: Immuno-Biological Labs Enters Into Licensing Agreement With IBL International
Table 99: MDxHealth Enters Into Licensing Agreement With Merck For MGMT Diagnostic Test
Table 100: CogState Enters Into Licensing Agreement With Merck Canada For Cognition Test
...

LIST OF FIGURES

Figure 1: In Vitro Diagnostics, Market Segmentation
Figure 2: In Vitro Diagnostics, Canada, Overall Revenue ($m) , USD Constant, 2004-2018
Figure 3: In Vitro Diagnostics Market, Canada, Revenue Mix ($m), 2011
Figure 4: In Vitro Diagnostics Market, Canada, Category Contribution (%), 2011
Figure 5: In Vitro Diagnostics Market, Canada, Cross-Category Analysis, 2004-2018
Figure 6: In Vitro Diagnostics, Canada, Overall Revenue ($m), USD Constant, Historic, 2004-2011
Figure 7: In Vitro Diagnostics, Canada, Overall Revenue ($m), USD Constant, Forecast, 2011-2018
Figure 8: In Vitro Diagnostics, Canada, Company Share (%), 2011
Figure 9: Clinical Chemistry, Market Segmentation
Figure 10: Clinical Chemistry Market, Canada, Revenue Mix ($m), 2011
Figure 11: Clinical Chemistry Market, Canada, Segment Contribution (%), 2011
Figure 12: Clinical Chemistry, Canada, Revenue ($m) USD Constant, by Segment , Historic, 2004-2011
Figure 13: Clinical Chemistry, Canada, Revenue ($m) USD Constant, by Segment , Forecast, 2011-2018
Figure 14: Clinical Chemisty Analyzers, Canada, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Figure 15: Clinical Chemisty Analyzers, Canada, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Figure 16: Urine Analysis, Canada, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Figure 17: Urine Analysis, Canada, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Figure 18: Clinical Chemistry, Canada, Company Share (%), 2011
Figure 19: Genetic Testing, Market Segmentation
Figure 20: Genetic Testing Market, Canada, Revenue Mix ($m), 2011
Figure 21: Genetic Testing Market, Canada, Segment Contribution (%), 2011
Figure 22: Genetic Testing, Canada, Revenue ($m) USD Constant, by Segment , Historic, 2004-2011
Figure 23: Genetic Testing, Canada, Revenue ($m) USD Constant, by Segment , Forecast, 2011-2018
Figure 24: Genetic Testing, Canada, Company Share (%), 2011
Figure 25: Haematology Market, Market Segmentation
Figure 26: Haematology Market, Canada, Revenue Mix ($m), 2011
Figure 27: Haematology Market, Canada, Segment Contribution (%), 2011
Figure 28: Haematology, Canada, Revenue ($m) USD Constant, by Segment , Historic, 2004-2011
Figure 29: Haematology, Canada, Revenue ($m) USD Constant, by Segment , Forecast, 2011-2018
Figure 30: Haematology Reagents, Canada, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Figure 31: Haematology Reagents, Canada, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Figure 32: Immunohaematology, Canada, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Figure 33: Immunohaematology, Canada, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Figure 34: Haemostasis, Canada, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Figure 35: Haemostasis, Canada, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Figure 36: Haematology Rapid Tests, Canada, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Figure 37: Haematology Rapid Tests, Canada, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Figure 38: Haematology Cell Counters, Canada, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Figure 39: Haematology Cell Counters, Canada, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Figure 40: Haematology, Canada, Company Share (%), 2011
Figure 41: Histology and Cytology Market, Market Segmentation
Figure 42: Histology And Cytology Market, Canada, Revenue Mix ($m), 2011
Figure 43: Histology And Cytology Market, Canada, Segment Contribution (%), 2011
Figure 44: Histology And Cytology, Canada, Revenue ($m) USD Constant, by Segment , Historic, 2004-2011
Figure 45: Histology And Cytology, Canada, Revenue ($m) USD Constant, by Segment , Forecast, 2011-2018
Figure 46: Histology And Cytology, Canada, Company Share (%), 2011
Figure 47: Immuno Chemistry Market, Canada, Revenue Mix ($m), 2011
Figure 48: Immuno Chemistry Market, Canada, Segment Contribution (%), 2011
Figure 49: Immuno Chemistry, Canada, Revenue ($m) USD Constant, by Segment , Historic, 2004-2011
Figure 50: Immuno Chemistry, Canada, Revenue ($m) USD Constant, by Segment , Forecast, 2011-2018
Figure 51: Disease Specific Immunochemistry, Canada, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Figure 52: Disease Specific Immunochemistry, Canada, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Figure 53: Drugs of Abuse / Toxicology, Canada, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Figure 54: Drugs of Abuse / Toxicology, Canada, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Figure 55: Endocrinology Tests, Canada, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Figure 56: Endocrinology Tests, Canada, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Figure 57: Immunochemistry Rapid Tests, Canada, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Figure 58: Immunochemistry Rapid Tests, Canada, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Figure 59: Therapeutic Drug Monitoring, Canada, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Figure 60: Therapeutic Drug Monitoring, Canada, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Figure 61: Immunochemistry Analyzers, Canada, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Figure 62: Immunochemistry Analyzers, Canada, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Figure 63: Immuno Chemistry, Canada, Company Share (%), 2011
Figure 64: Infectious Immunology, Market Segmentation
Figure 65: Infectious Immunology Market, Canada, Revenue Mix ($m), 2011
Figure 66: Infectious Immunology Market, Canada, Segment Contribution (%), 2011
Figure 67: Infectious Immunology, Canada, Revenue ($m) USD Constant, by Segment , Historic, 2004-2011
Figure 68: Infectious Immunology, Canada, Revenue ($m) USD Constant, by Segment , Forecast, 2011-2018
Figure 69: Infectious Immunology Rapid Tests, Canada, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Figure 70: Infectious Immunology Rapid Tests, Canada, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Figure 71: Infectious Immunology, Canada, Company Share (%), 2011
Figure 72: Microbiology Culture, Market Segmentation
Figure 73: Microbiology Culture Market, Canada, Revenue Mix ($m), 2011
Figure 74: Microbiology Culture Market, Canada, Segment Contribution (%), 2011
Figure 75: Microbiology Culture, Canada, Revenue ($m) USD Constant, by Segment , Historic, 2004-2011
Figure 76: Microbiology Culture, Canada, Revenue ($m) USD Constant, by Segment , Forecast, 2011-2018
Figure 77: Microbiology Analyzers, Canada, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Figure 78: Microbiology Analyzers, Canada, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Figure 79: Microbiology Culture, Canada, Company Share (%), 2011
Figure 80: Siemens Healthcare, Company Share (%),Canada In Vitro Diagnostics Market, 2011
Figure 81: Abbott Laboratories, Company Share (%),Canada In Vitro Diagnostics Market, 2011
Figure 82: F. Hoffmann-La Roche Ltd., Company Share (%),Canada In Vitro Diagnostics Market, 2011
Figure 83: Beckman Coulter, Inc, Company Share (%),Canada In Vitro Diagnostics Market, 2011
Figure 84: Ortho-Clinical Diagnostics Inc., Company Share (%),Canada In Vitro Diagnostics Market, 2011
Figure 85: Alere Inc., Company Share (%),Canada In Vitro Diagnostics Market, 2011

COMPANIES MENTIONED

Siemens Healthcare
Abbott Laboratories
F. Hoffmann-La Roche Ltd.
Beckman Coulter, Inc.
Ortho-Clinical Diagnostics Inc.
Alere Inc.
Danaher Corporation.
bioMerieux S.A.
Becton, Dickinson and Company
Bio-Rad Laboratories, Inc.
Biomedica Diagnostics Inc.
Sysmex Corporation
Gen-Probe Incorporated
Qiagen N.V.
DiaSorin S.p.A
Thermo Fisher Scientific Inc.
Immucor, Inc.
Hologic, Inc.
Olympus Corporation
PerkinElmer, Inc.
Grifols, S.A.
Life Technologies Corporation
ELITech Group
Horiba, Ltd.
Diagnostica Stago, Inc.

Ask Your Question

Canada In Vitro Diagnostics Market Outlook to 2018- Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry and Microbiology Culture
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: